Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 219

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Field Trip Announces Intention to Make Applications on Behalf of Patients...

PharmaTher Announces Publication of Research Data for KETABET™

Filament Health Announces Health Canada Approval for Phase II Trial Administering...

Psychedelic Drug Policy Reform in 2021

Psychedelics 2021: A Year in Review

The McQuade Center for Strategic Research and Development and Mindset Pharma...

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board...

PT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

COMP360 psilocybin study of 89 healthy participants published in Journal of...

Load more

EDITOR PICKS

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to...

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©